Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma Excellence Forum

Diffuse Large B-Cell Lymphoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Jeremy Abramson, MD
Conference Coverage
Glofitamab Plus Gemcitabine and Oxaliplatin Demonstrates Benefit for Patients With R/R Diffuse Large B-Cell Lymphoma
06/27/2024
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data...
06/27/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Odronextamab Demonstrates Efficacy, Safety for Heavily Pretreated Patients With DLBCL Progressing After CAR T-Cell Therapy
06/26/2024
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data...
06/26/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Evaluating the Efficacy of Odronextamab Plus CHOP vs R-CHOP Among Patients With Previously Untreated DLBCL
06/11/2024

Featuring Matthew Matasar, MD

Featuring Matthew Matasar, MD
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses...
06/11/2024
Oncology
David Andorsky, MD, Rocky Mountain Cancer Centers
Videos
Significance of Patient Enrollment in Lymphoma Clinical Trials, Particularly Among Older Patients
06/04/2024

Featuring David Andorsky, MD

Featuring David Andorsky, MD
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares...
06/04/2024
Oncology
Sam Yamshon, MD, Weill Cornell Medicine
Conference Coverage
Safety of CAR T-Cell Therapy Following FDA Warning on Risk of Secondary Malignancies Following Treatment
05/06/2024

Featuring Sam Yamshon, MD

Featuring Sam Yamshon, MD
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the...
05/06/2024
Oncology
Jennifer Amengual, MD, Columbia University
Conference Coverage
Novel Therapeutic Targets for Elderly Patients With Diffuse Large B-Cell Lymphoma
05/06/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jennifer Amengual, MD, discusses novel therapeutic targets for elderly patients with DLBCL who are not candidates for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jennifer Amengual, MD, discusses novel therapeutic targets for elderly patients with DLBCL who are not candidates for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
05/06/2024
Oncology
Samuel Yamshon, MD
Conference Coverage
Examining the Efficacy of CAR T-Cell Therapy Among Elderly Patients With R/R DLBCL
04/06/2024

Featuring Samuel Yamshon, MD

Featuring Samuel Yamshon, MD
During the Great Debates & Updates in Hematologic Malignancies meeting, Samuel Yamshon, MD, examines the efficacy of using CAR T-cell therapy to treat elderly patients with relapsed/refractory diffuse large B-cell lymphoma.
During the Great Debates & Updates in Hematologic Malignancies meeting, Samuel Yamshon, MD, examines the efficacy of using CAR T-cell therapy to treat elderly patients with relapsed/refractory diffuse large B-cell lymphoma.
During the Great Debates &...
04/06/2024
Oncology
Jennifer Amengual, MD, Columbia University
Conference Coverage
Exploring Treatment Strategies for Elderly Patients With Aggressive Lymphoma Ineligible for CAR T-Cell Therapy
03/11/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
03/11/2024
Lymphoma, Leukemia & Myeloma Network
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
Analyzing Immunotherapy Options for the Treatment of Patients With Large-Cell Lymphoma
02/26/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, discusses up and coming treatment developments on the horizon within the large-cell lymphoma research space, focusing on the importance of immunotherapy.
Andrew Zelenetz, MD, discusses up and coming treatment developments on the horizon within the large-cell lymphoma research space, focusing on the importance of immunotherapy.
Andrew Zelenetz, MD, discusses...
02/26/2024
Oncology
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
R-CHOP Followed by R-ICE Treatment Shows Potential for Patients With Non-GCB DLBCL
02/26/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, shares study results that suggest sequential rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) induction followed by rituximab, ifosfamide, carboplatin, and etoposide ([R]-ICE) consolidation...
Andrew Zelenetz, MD, shares study results that suggest sequential rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) induction followed by rituximab, ifosfamide, carboplatin, and etoposide ([R]-ICE) consolidation...
Andrew Zelenetz, MD, shares...
02/26/2024
Oncology

Advertisement

Recent Stories

Jeremy Abramson, MD
Conference Coverage
Glofitamab Plus Gemcitabine and Oxaliplatin Demonstrates Benefit for Patients With R/R Diffuse Large B-Cell Lymphoma
06/27/2024
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data...
06/27/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Odronextamab Demonstrates Efficacy, Safety for Heavily Pretreated Patients With DLBCL Progressing After CAR T-Cell Therapy
06/26/2024
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data...
06/26/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Evaluating the Efficacy of Odronextamab Plus CHOP vs R-CHOP Among Patients With Previously Untreated DLBCL
06/11/2024

Featuring Matthew Matasar, MD

Featuring Matthew Matasar, MD
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses...
06/11/2024
Oncology
David Andorsky, MD, Rocky Mountain Cancer Centers
Videos
Significance of Patient Enrollment in Lymphoma Clinical Trials, Particularly Among Older Patients
06/04/2024

Featuring David Andorsky, MD

Featuring David Andorsky, MD
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares...
06/04/2024
Oncology
Sam Yamshon, MD, Weill Cornell Medicine
Conference Coverage
Safety of CAR T-Cell Therapy Following FDA Warning on Risk of Secondary Malignancies Following Treatment
05/06/2024

Featuring Sam Yamshon, MD

Featuring Sam Yamshon, MD
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the...
05/06/2024
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement